… We analyzed the EGFR mutation pattern of 79 cases of NSCLC harboring EGFR mutations
and … data for patients with NSCLCs with compound EGFR mutations treated with EGFR TKIs. …

… the tyrosine kinase domain of EGFR. Subsequent reports indicated that the somatic mutational
status of EGFR … Since the first reports of somatic EGFR mutations in NSCLC, a plethora of …

… tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, are reversible competitive
inhibitors of the tyrosine kinase domain of EGFR … Somatic activating mutations of the EGFR gene, …

… the kinase domain of EGFR have been developed and are clinically active. More importantly,
such tyrosine kinase … activating mutations in the tyrosine kinase domain of the EGFR gene. …

… of EGFR to lung cancers supports the concept of ‘oncogene addiction’. Tyrosine kinase …
the cancer harboring EGFR mutations or aberrant activation of EGFR. TKIs can inhibit the …

… part of the tyrosine kinase domain of the … EGFR tyrosine kinase inhibitor (TKI), gefitinib,
compared with standard chemotherapy as first line therapy for patients harboring EGFR mutations …

… Also in this study, patients were stratified by EGFR mutation (L858R, exon 19 deletions or
other). Afatinib improved PFS, the primary endpoint, compared with chemotherapy (11 vs. 5.6 …

… a variety of novel EGFR resistance mutations. We confirmed that … irreversible kinase inhibitors
is significantly affected by mutation … can influence the EGFR mutation spectrum induced by …

… In this study, we aimed to assess the role of TP53 mutation in a cohort of EGFR-mutated …
and the different types of mutation, in relation to the different EGFR mutations and outcomes of …

… in the EGFR mutation status between … of EGFR mutations is available, and this hypothesis
has remained untested [12–14]. For this reason, we studied discordance in the EGFR mutation …